


PF-06424439

Cat. No.:	HY-108341
CAS No.:	1469284-78-3
Molecular Formula:	C ₂₂ H ₂₆ ClN ₇ O
Molecular Weight:	439.94
Target:	Acyltransferase
Pathway:	Metabolic Enzyme/Protease
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.



BIOLOGICAL ACTIVITY

Description	PF-06424439 is an oral, potent and selective imidazopyridine diacylglycerol acyltransferase 2 (DGAT2) inhibitor with an IC ₅₀ of 14 nM ^[1] . PF-06424439 is slowly reversible, time-dependent inhibitor, which inhibits DGAT2 in a noncompetitive mode with respect to the acyl-CoA substrate ^[2] .																
IC₅₀ & Target	IC ₅₀ : 14 nM (DGAT2) ^[1]																
In Vivo	<p>PF-06424439 (p.o.; 60 mg/kg/day; for 3 days) reduces plasma triglyceride (TG) and cholesterol levels and decreases nonsignificant in circulating lipids in mice (Ldlr^{-/-})^[1].</p> <p>PF-06424439 (i.v.; 1 mg/kg) shows moderate clearance in rats following intravenous administration and moderate steady-state volume of distribution (Vdss) results in a short half-life^[1].</p> <p>MCE has not independently confirmed the accuracy of these methods. They are for reference only.</p> <table border="1"> <tr> <td>Animal Model:</td> <td>Male low-density lipoprotein receptor (Ldlr) knockout mice (Ldlr^{-/-})^[1]</td> </tr> <tr> <td>Dosage:</td> <td>60 mg/kg</td> </tr> <tr> <td>Administration:</td> <td>P.o.; daily; for 3 days</td> </tr> <tr> <td>Result:</td> <td>Reduced plasma TG and cholesterol levels and decreased nonsignificant in circulating lipids.</td> </tr> </table> <table border="1"> <tr> <td>Animal Model:</td> <td>Male Wistar-Han rats^[1]</td> </tr> <tr> <td>Dosage:</td> <td>1 mg/kg</td> </tr> <tr> <td>Administration:</td> <td>I.v.</td> </tr> <tr> <td>Result:</td> <td>Showed moderate clearance and a short half-life with t_{1/2}=1.39 h.</td> </tr> </table>	Animal Model:	Male low-density lipoprotein receptor (Ldlr) knockout mice (Ldlr ^{-/-}) ^[1]	Dosage:	60 mg/kg	Administration:	P.o.; daily; for 3 days	Result:	Reduced plasma TG and cholesterol levels and decreased nonsignificant in circulating lipids.	Animal Model:	Male Wistar-Han rats ^[1]	Dosage:	1 mg/kg	Administration:	I.v.	Result:	Showed moderate clearance and a short half-life with t _{1/2} =1.39 h.
Animal Model:	Male low-density lipoprotein receptor (Ldlr) knockout mice (Ldlr ^{-/-}) ^[1]																
Dosage:	60 mg/kg																
Administration:	P.o.; daily; for 3 days																
Result:	Reduced plasma TG and cholesterol levels and decreased nonsignificant in circulating lipids.																
Animal Model:	Male Wistar-Han rats ^[1]																
Dosage:	1 mg/kg																
Administration:	I.v.																
Result:	Showed moderate clearance and a short half-life with t _{1/2} =1.39 h.																

REFERENCES

[1]. Futatsugi K, et al. Discovery and Optimization of Imidazopyridine-Based Inhibitors of Diacylglycerol Acyltransferase 2 (DGAT2). J Med Chem. 2015 Sep 24;58(18):7173-85.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA